Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study

Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchi, Francesco, Rollini, Fabiana, Kairouz, Victor, Rivas Rios, Jose, Rivas, Andrea, Agarwal, Malhar, Briceno, Maryuri, Wali, Mustafa, Nawaz, Ahmed, Silva, Gabriel, Shaikh, Zubair, Maaliki, Naji, Been, Latonya, Piraino, Jason, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Jennings, Lisa K., Bass, Theodore A., Angiolillo, Dominick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
CLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978557/
https://www.ncbi.nlm.nih.gov/pubmed/31998847
http://dx.doi.org/10.1016/j.jacbts.2019.07.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978557/
https://www.ncbi.nlm.nih.gov/pubmed/31998847
http://dx.doi.org/10.1016/j.jacbts.2019.07.011

Ejemplares similares